microarrays containing representative genes associated with pathways specific for apoptosis or cell proliferation  (SuperArray Bioscience Corporation)

Journal: iScience

Article Title: Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity

doi: 10.1016/j.isci.2026.116022

Figure Lengend Snippet: BNT351 shows comparable target affinity to 1-18 and no off-target binding (A) Left: the binding affinity of BNT351 and 1-18 to the stabilized HIV-1 envelope protein trimer (SOSIP BG505.664 ) by SPR (mean and individual values of triplicate measurements). Also see A. Right: binding of BNT351 and 1-18 to SOSIP BG505.664 by ELISA (mean ± standard deviation of triplicate measurements). (B) BNT351’s off-target binding was assessed by Retrogenix Cell Microarray Technology platform. Interactions identified during the library screen with ∼6,500 human proteins are shown. Also, see . Interaction with pepsinogen C (PGC) that appeared to be specific was re-tested by flow cytometry with HEK293 cells transfected with PGC. HEK293 cells transfected with FcγRIIIa and FcεRIg were used as a positive control. Duplicate measurements are shown for flow cytometry.

Article Snippet: The Retrogenix cell microarray was performed by Charles River Laboratories and included 6,105 full-length human proteins (plasma membrane proteins, secreted or a cell surface-tethered secreted proteins) and 400 human heterodimers.

Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Standard Deviation, Microarray, Flow Cytometry, Transfection, Positive Control